LBP and COVID-19: Of note, levels of LBP and the CCR9 ligand CCL25 were elevated in COVID‐19 patients, and it is tempting to hypothesize that LPS and CCL25 could contribute to gut mucosal impairment through promoting intestinal inflammation [37].